The "Risk" in Pediatric Low-Grade Glioma

Jason Fangusaro; Pratiti Bandopadhayay

doi:10.1016/j.ccell.2020.03.020

The "Risk" in Pediatric Low-Grade Glioma

Cancer Cell. 2020 Apr 13;37(4):424-425. doi: 10.1016/j.ccell.2020.03.020.

Authors

Jason Fangusaro¹, Pratiti Bandopadhayay²

Affiliations

¹ Department of Pediatric Hematology and Oncology, Children's Healthcare of Atlanta, Atlanta, GA, USA; Aflac Cancer and Blood Disorder Center, Atlanta, GA, USA; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: jfangus@emory.edu.
² Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.

PMID: 32289265
DOI: 10.1016/j.ccell.2020.03.020

Abstract

In this issue of Cancer Cell, Ryall et al. report on the largest clinically and molecularly characterized cohort of pediatric low-grade gliomas (pLGGs) published to date. They provide new insight into the pLGG molecular landscape and a novel risk stratification system with the potential to revolutionize prognostication and impact treatment.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Child
Cohort Studies
Glioma* / genetics
Humans